Efficacy and Safety of Anti-integrin and Sphingosine-1-Phosphate (S1P)-1 Receptor Modulators with Drs. Bruce E. Sands and William J. Sandborn
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-integrin and S1P-1 receptor modulators, that are in late-stage development for treating moderate to sev...
16 Maalis 202115min
Mechanisms of Action of New Classes of Agents for Moderate to Severe Crohn's Disease with Drs. William J. Sandborn and Bruce E. Sands
In this podcast, expert clinicians will discuss emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn's disease.
16 Maalis 202119min
Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 Inhibitors
Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 InhibitorsInflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn's disease, affects an estimated 3 million adults in...
29 Huhti 201912min
Investigational Agents in Ulcerative Colitis: JAK Inhibitors and S1P Receptor Modulators
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn's disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the tr...
29 Huhti 20199min
Investigational Agents in Ulcerative Colitis: Anti-Integrins
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn's disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the tr...
25 Huhti 20199min
Ulcerative Colitis: Targeting Immunological Pathways in Moderate to Severe Disease – Updates From Copenhagen
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn's disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the tr...
25 Huhti 201948s
